Equine growth hormone. Detection of immunoreactive sequences using poly- and monoclonal antibodies.

This study looks at the immunological responses of various fragments of equine growth hormone (eGH) when exposed to different types of antibodies. The research revealed specific sequences that were recognized by these antibodies, as well as some differences in recognition between native and modified versions of the hormone.

Research on Equine Growth Hormone

• This study examined several fragments of equine growth hormone, a hormone produced by horses that promotes growth and regulates metabolism.
• The team of researchers used competitive binding assays, a process measuring the interaction between a specific antibody and its target antigen, to study the sequences of this hormone.

Role of Antibodies

• The researchers employed antibodies to eGH sourced from different locations. These included rabbit antibodies to eGH and three mouse monoclonal antibodies (MAbs).
• These antibodies were shown to detect antigenicity – the capacity to stimulate an immune response – within the sequences 5-72 and 73-123 of eGH. They were generated by using bovine growth hormone as an immunogen, a substance that stimulates an immune response.

Identified Immunoreactive Sequences

• The polyclonal antibodies to eGH also recognized two smaller peptides, 52-72 and 110-123. These sequences are blocks of amino acid residues that form part of the larger hormone sequence.
• Interestingly, antibodies produced in hypopituitary patients who had been injected with human growth hormone for therapeutic purposes did not react with any fragment derived from eGH.

Comparison of Native and Modified eGH

• The rabbit polyclonal antibodies and mouse monoclonal antibodies scarcely differentiated between the native and a chemically modified version of eGH, called S-carbamidomethylated eGH.
• However, the patient-derived human antibodies detected a significant difference between the native and the modified hormone. This difference implicates a potential disparity in how these two versions of the hormone would be recognized by the human immune system.